3′ CBFβ deletion associated with inv(16) in acute myeloid leukemia

Cancer Genetics and Cytogenetics

Volumn 162, Issue 2, 2005, Pages 122-126

  Kelly, Johanna ^a   Foot, Nicola J ^b   Conneally, Eibhlin ^c   Enright, Helen ^d   Humphreys, Mervyn ^e   Saunders, Karen ^f   Neat, Michael J ^a  

^a OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c ST JAMES S HOSPITAL   (Ireland)

^d ADELAIDE AND MEATH HOSPITAL   (Ireland)

^e BELFAST CITY HOSPITAL   (United Kingdom)

^f Rayne Institute ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CORE BINDING FACTOR; CORE BINDING FACTOR BETA; NUCLEIC ACID BINDING PROTEIN; UNCLASSIFIED DRUG; CBFB PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CASE REPORT; CHROMOSOME ANALYSIS; CHROMOSOME INVERSION; CHROMOSOME INVERSION 9; CHROMOSOME TRANSLOCATION 16; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; ACUTE DISEASE; CHROMOSOME 16; CHROMOSOME DELETION; GENETICS; MYELOID LEUKEMIA;

ACUTE DISEASE; ADULT; AGED; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 16; CORE BINDING FACTOR BETA SUBUNIT; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INVERSION, CHROMOSOME; LEUKEMIA, MYELOID; MALE;

EID: 26444441315     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2005.03.001     Document Type: Article

References (35)

1. M.M. Le Beau, R.A. Larson, M.A. Bitter, J.W. Vardiman, H.M. Golomb, and J.D. Rowley Association of an inversion chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukaemia: A unique cytogenetic- clinicopathological association N Engl J Med 309 1983 630 636
2. S.E. Langebeer, H. Walker, R.E. Gale, K. Wheatley, A.K. Burnett, A.H. Goldstone, and D. Linch Frequency of CBFβ/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials Br J Haematol 96 1997 736 739
3. D. Grimwade, H. Walker, F. Oliver, K. Wheatley, C. Harrison, G. Harrison, J. Rees, I. Hann, R. Stevens, A. Burnett, and A. Goldstone The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial Blood 92 1998 2322 2333
4. C. Schoch, S. Schnittger, W. Kern, M. Dugas, W. Hiddemann, and T. Haferlach Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia Haematologica 2003 351 353
5. M. Mitterbauer, K. Laczika, M. Novak, G. Mitterbauer, B. Hilgarth, H. Pirc-Danoewinata, I. Schwarzinger, O.A. Haas, C. Fonatsch, K. Lechner, and U. Jaeger High concordance of karyotype analysis and RT-PCR for CBFbeta/MYH11 in unselected patients with acute myeloid leukemia. A single center study Am J Clin Pathol 113 2000 406 410
6. DJ, S.J. Vickers, J. Bryon, D.J. McMullan, M.J. Griffiths, J.T. Reilly, E.A. Vandenberghe, G. Wilson, A.E. Watmore, and N.P. Bown Cytogenetically cryptic AML1-ETO and CBFβ-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia BJ Haematology 111 2000 1051 1056
7. P. Liu, D.F. Claxton, P. Marlton, A. Hajra, J. Siciliano, M. Freedman, S.C. Chandrasekharappa, K. Yanagisawa, R.L. Stallings, F.S. Collins, and M.J. Siciliano Identification of yeast artificial chromosomes containing the inversion 16 p-arm breakpoint associated with acute myelomonocytic leukemia Blood 82 1993 716 721
8. P. Liu, S.A. Tarle, A. Hajra, D.F. Claxton, P. Marlton, M. Freedman, M.J. Siciliano, and F.S. Collins Fusion between transcription factor CBFBbeta/PEBP2P and a myosin heavy chain in acute myeloid leukemia Science 261 1993 1041 1044
9. P. Marlton, D.F. Claxton, P. Liu, E.H. Estey, M. Beran, M. Le Beau, J.R. Testa, F.S. Collins, J.D. Rowley, and M.J. Siciliano Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis Blood 85 1995 772 779
10. D. Martinet, D. Muhlematter, M. Leeman, V. Parlier, U. Hess, J. Gmur, and M. Jotterand Detection of 16p deletions by FISH in patients with inv(16) or t(16;16) and acute myeloid leukaemia (AML) Leukaemia 11 1997 964 970
11. J. Byrd, K. Mrozek, R.K. Dodge, A.J. Carroll, C.G. Edwards, D.C. Arthur, M.J. Pettanati, S.R. Patil, K.W. Rao, M.S. Watson, P.R.K. Koduru, J.O. Moore, R.M. Stone, R.J. Mayer, E.J. Feldman, F.R. Davey, C.A. Schiffer, R.A. Larson, and C.D. Bloomfield Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukaemia: results from Cancer and Leukaemia Group B (CALGB 8461) Blood 100 2002 4325 4336
12. C.D. Bloomfield, C. Shuma, L. Regal, P.P. Philip, D.K. Hossfeld, A.M. Hagemeijer, O.M. Garson, B.A. Peterson, M. Sakurai, G. Alimena, R. Berger, J.D. Rowley, T. Ruutu, F. Mitelman, G.W. Dewald, and J. Swansbury Long-term survival of patients with acute myeloid leukaemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukaemia Cancer 80 1997 2191 2198
13. J. Delaunay, N. Vey, T. Leblanc, P. Fenaux, F. Rigal-Huguet, F. Witz, T. Lamy, A. Auvrignon, D. Blaise, A. Pigneux, F. Mugneret, C. Bastard, N. Dastugue, J. Van den Akker, D. Fière, J. Reiffers, S. Castaigne, G. Leverger, J.-L. Harousseau, and H. Dombret Prognosis of inv(16)/t(16;16) acute myeloid leukaemia (AML): a survey of 110 cases from the French AML Intergroup Blood 102 2003 462 469
14. C.D. Bloomfield, D. Lawrence, J.C. Byrd, A. Carroll, M.J. Pettenati, R. Tantravahi, S.R. Patil, F.R. Davey, D.T. Berg, C.A. Schiffer, D.C. Arthur, and R.J. Mayer Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype Cancer Res 58 1998 4173 4179
15. B.I. Razzouk, S.C. Raimondi, D.K. Srivastava, M. Pritchard, F.G. Behm, X. Tong, J.T. Sandlund, J.E. Rubnitz, C.-H. Pui, and R.C. Ribeiro Impact of treatment on the outcome of acute myeloid leukaemia with inversion 16: a single institution's experience Leukemia 15 2001 1326 1330
16. C. Herens, F. Tassin, V. Lemaire, Y. Beguin, E. Collard, S. Lampertz, C. Croisiau, M. Lecomte, B. De Prijk, L. Longrée, and L. Koulischer Deletion of the 5′-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients Br J Haematol 110 2000 214 216
17. P.B. Sinclair, E.B. Nacheva, M. Leversha, N. Telford, J. Chang, A. Reid, A. Bench, K. Champion, B. Huntly, and A.R. Green Large deletions at the t(9;22) breakpoint are common and may identify a poor prognosis subgroup of patients with chronic myeloid leukaemia Blood 95 2000 738 744
18. N. Cohen, G. Rozenfeld-Granot, I. Hardan, F. Brok-Simoni, N. Amariglio, G. Rechavi, and L. Trakhtenbrot Subgroup of patients with Philadelphia-positive chronic myelogenous leukaemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis Cancer Genet Cytogenet 128 2001 114 119
19. B. Huntly, A.G. Reid, A.J. Bench, L.J. Campbell, N. Telford, P. Shepherd, J. Szer, H.M. Prince, P. Turner, C. Grace, E.P. Nacheva, and A.R. Green Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukaemia Blood 98 2001 1732 1738
20. B.J.P. Huntly, A. Bench, and A.R. Green Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukaemia Blood 102 2003 1160 1168
21. B.J.P. Huntly, A.J. Bench, E. Delabesse, A.G. Reid, J. Li, M.A. Scott, L. Campbell, J. Byrne, E. Pinto, A. Brizard, D. Niedermeiser, E.P. Nacheva, F. Guilhot, M. Deininger, and A.R. Green Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability Blood 99 2002 4547 4553
22. K. Dohner, R.F. Schlenk, B.A. Van der Reijden, and H. Dohner Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukaemia with inversion of chromosome 16 has no prognostic impact Leukaemia 14 2000 1154
23. D. Van der Kolk, E. Vallenga, A.Y. Van der Veen, L. Noordhoek, H. Timmer-Bosscha, G.J. Ossenkoppele, R.A. Raymakers, M. Muller, E. Van den Berg, and E.G.E. de Vries Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukaemia: the impact on MRP activity Blood 95 2000 3514 3519
24. J.R. Batanian, Y. Huang, and R. Fallon Deletion of 3′-CBFB gene in association with an inversion (16)(p13q22) and a loss of the Y chromosome in a 2-year-old child with acute myelogenous leukaemia-M4 Cancer Genet Cytogenet 121 2000 216 219
25. E. Kolomietz, J. Al-Maghrabi, S. Brennan, J. Karaskova, S. Minkin, J. Lipton, and J.A. Squire Primary chromosomal rearrangements of leukaemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis Blood 97 2001 3581 3588
26. N. Egan, J. O'Reilly, L. Chipper, M. Higgins, R. Herrmann, and P. Cannell Deletion of CBFB in a patient with acute myelomonocytic leukemia (AML M4Eo) and inversion 16 Cancer Genet Cytogenet 154 2004 60 62
27. C. Godon, J. Proffitt, N. Dastugue, M. Lafage-Pochitaloff, M.-J. Mozziconacci, P. Talmant, M. Hackbarth, and R. Bataille Large deletions 5′ to the ETO breakpoint are recurrent events in patients with t(8;21) acute myeloid leukaemia Leukemia 16 2001 1752 1754
28. J. Corral, A. Forster, S. Thompson, F. Lampert, Y. Kaneko, R. Slater, W.G. Kroes, C.E. Van der Schoot, W. Ludwig, A. Karpas, C. Pocock, F. Cotter, and T. Rabbitts Acute leukemias of different lineages have similar MLL gene fusions encoding related chimeric proteins resulting from chromosomal translocation Proc Natl Acad Sci USA 90 1993 8538 8542
29. M. Baens, A. Steyls, J. Dierlamm, C. De Wolf-Peeters, and P. Marynen Structure of the MLT gene and molecular characterization of the genomic breakpoint junctions in the t(11;18)(q21;q21) of marginal zone B-cell lymphomas of MALT type Genes Chromosomes Cancer 29 2000 281 291
30. T. Akagi, M. Motegi, A. Tamura, R. Suzuki, Y. Hosokawa, H. Suzuki, H. Ota, S. Nakamura, Y. Morishima, M. Taniwaki, and M. Seto A novel gene, MALT1 at 18q21, is involved in t(11;18)(q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue Oncogene 18 1999 5785 5794
31. Y. Yoong, T.J. VanDeWalker, R.O. Carlson, G.W. Dewald, and A. Tefferi Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia Eur J Haematol 74 2005 124 127
32. B.J.P. Huntly, F. Guilhot, A.G. Reid, G. Vassiliou, E. Hennig, C. Franke, J. Byrne, A. Brizard, D. Niederwieser, J. Freeman-Edward, G. Cuthbert, N. Bown, R.E. Clark, E.P. Nacheva, A.R. Green, and M.W.N. Deininger Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions Blood 102 2003 2205 2212
33. B.H. Czepulkowski Basic techniques for the preparation and analysis of chromosomes from bone marrow and leukemic blood D.E. Rooney Human cytogenetics: malignancy and acquired abnormalities 2001 Oxford University Press Oxford 1 26
34. F. Mitelman ISCN: an international system for human cytogenetic nomenclature 1995 S. Karger Basel
35. J.V. Melo The diversity of BCR-ABL fusion proteins and their relationship to leukaemia phenotype Blood 88 1996 2375 2384